盐酸阿西米尼片Asciminib hydrochloride 40mg

This product is a kinase inhibitor indicated for the treatment of the following conditions: Chronic phase (CP) Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in patients previously treated with two or more tyrosine kinase inhibitors (TKIs). Chronic phase (CP) Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) with the T315I mutation.

Patient Population Recommended Dose Ph+ CML-CP patients 80 mg orally once daily; or 40 mg orally twice daily, with an interval of approximately 12 hours Ph+ CML-CP patients with T315I mutation 200 mg orally twice daily, with an interval of approximately 12 hours Administration Instructions: Administer orally on an empty stomach, at least 2 hours before or 1 hour after a meal. Treatment Duration: Continue therapy as long as clinical benefit is observed, until unacceptable toxicity occurs.

Myelosuppression: Severe thrombocytopenia and neutropenia may occur. Manage by interrupting treatment or reducing the dose. Pancreatic Toxicity: Monitor serum lipase and amylase levels. Hypersensitivity Reactions: Hypersensitivity reactions may occur. Cardiovascular Toxicity: Cardiovascular toxicity may occur. Embryo-Fetal Toxicity: May cause fetal harm.

Upper respiratory tract infection, musculoskeletal pain, decreased platelet count, increased triglycerides, decreased neutrophil count, elevated uric acid, headache, fatigue, nausea, rash, diarrhea.

60 tablets per bottle.

Store tightly closed and protected from moisture at room temperature (20℃–25℃). Keep out of the reach of children.